Valens Semiconductor to Participate in Upcoming Investor Conferences
Oppenheimer 28th Annual Technology, Internet & Communications ConferenceFormat: Presentation and virtual one-on-one meetingsWhen: Monday, August 11 to Wednesday, August 13. Presentation is scheduled for August 11 at 2:05 pm ETWebcast Link: https://wsw.com/webcast/oppenheimer43/vlncf/3007947
Needham 6th Annual Virtual Semiconductor & SemiCap ConferenceFormat: Virtual one-on-one meetingsWhen: Wednesday, August 20 and Thursday, August 21
Jefferies Semiconductor, IT Hardware & Communications ConferenceFormat: In-person one-on-one meetingsWhen: Tuesday, August 26Location: Chicago, IL
Evercore ISI Semi, IT Hardware & Networking ConferenceFormat: In-person one-on-one meetingsWhen: Wednesday, August 27Location: Chicago, IL
Investors interested in scheduling one on one meetings with Valens during any of the upcoming conferences are encouraged to contact their sales representative or reach out to Miri Segal at msegal@ms-ir.com.
About Valens Semiconductor
Valens Semiconductor (NYSE: VLN) is a leader in high-performance connectivity, enabling customers to transform the digital experiences of people worldwide. Valens' chipsets are integrated into countless devices from leading customers, powering state-of-the-art audio-video installations, next-generation videoconferencing, and enabling the evolution of ADAS and autonomous driving. Pushing the boundaries of connectivity, Valens sets the standard everywhere it operates, and its technology forms the basis for the leading industry standards such as HDBaseT® and MIPI A-PHY. For more information, visit https://www.valens.com.
Forward-Looking StatementsThis press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding our anticipated future results, including financial results, our five-year plan, currency exchange rates, and contract wins, and future economic and market conditions. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Valens Semiconductor's ("Valens") management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Valens Semiconductor. These forward-looking statements are subject to a number of risks and uncertainties, including the cyclicality of the semiconductor industry; the effect of inflation and a rising interest rate environment on our customers and industry; the ability of our customers to absorb inventory; competition in the semiconductor industry, and the failure to introduce new technologies and products in a timely manner to compete successfully against competitors; if Valens fails to adjust its supply chain volume due to changing market conditions or fails to estimate its customers' demand; disruptions in relationships with any one of Valens' key customers; any difficulty selling Valens' products if customers do not design its products into their product offerings; Valens' dependence on winning selection processes; even if Valens succeeds in winning selection processes for its products, Valens may not generate timely or sufficient net sales or margins from those wins; sustained yield problems or other delays or quality events in the manufacturing process of products; our ability to effectively manage, invest in, grow, and retain our sales force, research and development capabilities, marketing team and other key personnel; our ability to timely adjust product prices to customers following price increase by the supply chain; our ability to adjust our inventory level due to reduction in demand due to inventory buffers accrued by customers; our expectations regarding the outcome of any future litigation in which we are named as a party; our ability to adequately protect and defend our intellectual property and other proprietary rights; our ability to successfully integrate or otherwise achieve anticipated benefits from acquired businesses; the market price and trading volume of the Valens ordinary shares may be volatile and could decline significantly; further deterioration of macroeconomic conditions due to ongoing global political and economic uncertainty, including with respect to China-Taiwan relations and increasing trade and other tariff-related tensions (as our current guidance assumes the estimated production and/or demand impact on us of current tariff conditions); political, economic, governmental and tax consequences associated with our incorporation and location in Israel; and those factors discussed in Valens' Form 20-F filed with the SEC on February 26, 2025 under the heading "Risk Factors," and other documents of Valens filed, or to be filed, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Valens does not presently know or that Valens currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Valens' expectations, plans or forecasts of future events and views as of the date of this press release. Valens anticipates that subsequent events and developments may cause Valens' assessments to change. However, while Valens may elect to update these forward-looking statements at some point in the future, Valens specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Valens' assessment as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Logo: https://mma.prnewswire.com/media/2309625/5445979/Valens_Semiconductor_Logo.jpg
For more information, please contact:
Investor Contacts:
Michal Ben AriInvestor Relations ManagerValens Semiconductor Ltd.michal.benari@valens.com
Miri SegalMS-IR IR for Valensmsegal@ms-ir.com
Media Contact: Yoni DayanHead of CommunicationsValens Semiconductor Ltd.yoni.dayan@valens.com
View original content:https://www.prnewswire.com/news-releases/valens-semiconductor-to-participate-in-upcoming-investor-conferences-302524165.html
SOURCE Valens Semiconductor
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Could This Psychedelic Drug Stock Be a Top Buy for 2026?
Amid a global mental health crisis, the demand for new and effective treatment options is on the rise, particularly in the realm of psychedelic-assisted therapies. Experts believe the psychedelic drug market will grow from $4.1 billion in 2025 to an impressive $7.8 billion by 2030, reflecting a steady compound annual growth rate (CAGR) of 13.7%. As the space gains traction, one small biotech company has caught some investors' attention: Mind Medicine (MNMD), also known as MindMed for short. In its most recent earnings update, MindMed reported solid progress with enrollment across three pivotal Phase 3 trials for its lead candidate, MM120, a refined version of recreational drug lysergide d-tartrate (LSD) currently being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Topline data from these trials is expected in 2026, setting the stage for a potential commercial launch by 2028. And analysts are also beginning to take notice. Oppenheimer, for example, recently expressed optimism based on what it believes could be 'powerful' Phase 3 data next year. So, with clinical milestones approaching, would it be wise to buy the shares of this psychedelic drugmaker? About Mind Medicine Stock MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its most advanced program, MM120, is currently in Phase 3 trials for GAD. Another key candidate, MM402, an MDMA-related compound, is in Phase 1 trials and being studied for its potential to address core symptoms of autism spectrum disorder (ASD). With a pipeline focused on conditions that often lack effective long-term solutions, the company is aiming to bring a fresh approach to mental health treatment. Valued at roughly $747 million by market capitalization, shares of this psychedelic therapy-focused company are gaining traction as investors take note of its advancing clinical pipeline and growing role in mental health innovation. Over the past year, shares have risen 34%, and the rally has only intensified in 2025 with a year-to-date (YTD) gain of 41%. That easily tops the broader S&P 500 Index's ($SPX) 22% gain over the past year and its 8% rise so far this year. Most notably, MindMed has surged 49% in just the last three months, highlighting growing investor interest. A Look Inside Mind Medicine's Q2 Earnings MindMed's fiscal 2025 second-quarter earnings, released on July 31, painted a mixed picture as the company deepens its push into late-stage development. The pre-revenue biotech firm posted a loss of $0.50 per share, widening from a loss of $0.26 a year ago and missing Wall Street's forecast of a $0.38 loss per share. The shortfall was driven by a sharp increase in research and development expenses, which surged 103.5% year-over-year (YOY) to $29.8 million, primarily due to the advancement of the MM120 program. While the company is investing heavily in advancing the MM120 program, one area of concern is the limited insight into the treatment's long-term effectiveness. So far, Phase 2 data only tracks results up to 12 weeks, leaving questions about how durable the benefits may be over an extended period. That said, MindMed's financial position remains strong. As of June 30, the company reported $237.9 million in cash, cash equivalents, and investments, enough to support operations into 2027 and beyond the first topline readout from its Phase 3 MM120 ODT trial. Meanwhile, clinical progress continues to move forward. MindMed remains on schedule with enrollment across three pivotal Phase 3 trials — Voyage, Panorama, and Emerge — which are focused on MM120 ODT for the treatment of GAD and MDD. These studies are designed to assess the efficacy of MM120 ODT as a standalone treatment, without the need for psychotherapy. The company expects topline data from its Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half. What Do Analysts Think About Mind Medicine Stock While investors' reaction to the company's Q2 results was somewhat underwhelming, sentiment took a sharp positive turn on Aug. 4 when shares jumped nearly 11% following an upgrade from Oppenheimer. Analyst Jay Olson lifted the psychedelic drug developer to an 'Outperform' rating and set a 12- to 18-month price target of $25, citing the promising potential of its lead candidate, MM120. Olson highlighted MM120's 'unique clinical profile,' describing it as a pharmaceutical form of LSD that delivers a less intense but longer-lasting psychedelic experience compared to other approaches. The analyst also emphasized the drug's potential in treating neuropsychiatric conditions like GAD and MDD. Backing his optimism, Olson noted encouraging Phase 2 trial data for MM120 in GAD, which showed favorable remission rates as well as a favorable safety and tolerability profile over a 12-week period. In his view, MindMed remains undervalued and is strategically positioned ahead of its anticipated Phase 3 readout Overall, MNMD stock has earned a resounding vote of confidence on Wall Street, carrying a consensus rating of 'Strong Buy.' Of the 11 analysts covering the stock, a majority of 10 analysts recommend a "Strong Buy" while the remaining one gives a 'Moderate Buy' rating. The average analyst price target of $25 indicates significant upside potential of 157% from the current price levels. Final Thoughts While MindMed's journey comes with the usual biotech risks — especially given its pre-revenue status, rising R&D costs, and questions around the long-term durability of MM120's effects — the company's progress in late-stage trials, strong financial position, and growing confidence from Wall Street paint an encouraging picture. For investors comfortable with biotech volatility and looking to gain exposure to the emerging psychedelic therapy space, MindMed could be a promising buy ahead of its anticipated Phase 3 milestones in 2026. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
7 minutes ago
- Forbes
Google's Free AI for Colleges: Why Tech Giants Must Upskill Society
On August 6, 2025, Google CEO Sundar Pichai announced an initiative to provide free access to advanced AI tools and training programs for college students in the US, Japan, Korea, Indonesia and Brazil. This move signals that AI is quickly becoming as indispensable as computers in the early 2000s and the internet in the 2010s. For students, access to AI capabilities is no longer optional but is being made as a necessary part of learning. College Students to Generate Research Reports with Gemini 2.5 Pro for Free Google's new offerings include an array of sophisticated tools. Students can use Gemini 2.5 Pro, an advanced AI model capable of answering questions, generating images, and providing quick help with homework and writing tasks. The platform also features Deep Research, which streamlines the process of gathering in-depth, web-wide information for custom research reports. NotebookLM acts as a personal thinking assistant, helping students organize ideas. Veo 3 allows users to transform text or images into short videos with sound in just eight seconds. Additionally, Jules, an AI coding assistant, offers higher limits for asynchronous coding tasks. Students also enjoy 2 terabytes of storage across Google Photos, Drive, and Gmail. On top of these functions, Google introduces a new mode called Guided Learning in Gemini, which can show students step-by-step processes in solving a problem via rounds of conversations to help students 'understand' rather than giving 'answers' direclty. This array of resources signifies a profound shift: AI is becoming ingrained in education, akin to how digital tools revolutionized learning decades ago. However, more than many other technologies, AI frequently sparked debates over plagiarism and academic integrity. Just a few months ago, a grad student using AI on exams was expelled from the university. Now, the deployment of free AI tools to college students indicates a recognition that AI's role in education is becoming inevitable. Like the transition from handwritten theses to digital word processing, we can expect that possibly within a year or two, AI will be a routine part of students' academic workflows, from data analysis and presentations to group projects and writing assignments. This transformation presents both promising opportunities and notable challenges. On the positive side, democratizing access to AI enables students to learn more efficiently, explore broader and deeper materials, and develop skills aligned with the demands of the future workforce. Google's integration of career certificate programs alongside these AI tools exemplifies this approach, aiming to equip students with practical skills that will serve them in their careers. The History of Tech Companies Upskilling Society Looking back at the computer literacy boom of the 1970s and 2000s, tech giants like IBM and Microsoft played pivotal roles, not just by providing tools and resources but by fostering partnerships with educational institutions. For instance, in 1971, IBM initiated its Faculty Loan Program, under which IBM employees visited colleges training students of color and of diverse abilities. Microsoft initiated the Working Connections program in 1997 in collaboration with the American Association of Community Colleges to develop an IT curriculum serving students with limited resources. These collaborations produced generations of engineers and scientists who fueled industry growth. This corporate upskilling mirrored, and sometimes sparked, broader open education movements. When MIT launched the OpenCourseWare in 2001, it demonstrated how technology could democratize elite curricula. Later, edX (co-founded by Harvard and MIT) scaled this globally. Recently, MIT just launched a new platform called the MIT Learn to continue this tradition, offering over 12,000 items of free resources in everything from machine learning ethics to cell biology. Today, Google is well-positioned to play a similar role, leveraging its scale, resources, and industry ties to train the next generation of skilled workers. Google's extensive infrastructure and established networks afford it a strategic advantage in deploying large-scale, impactful educational initiatives. But AI start-ups such as OpenAI, Anthropic and many more should also join the effort to prepare the next generation with skills needed to succeed in the age of AI. When AI enhances productivity, potentially replacing many entry-level jobs, it becomes vital that the resulting surplus is reinvested into society, creating new opportunities rather than widening inequalities. Upskilling or Deskilling: the Risks of Overreliance on AI Nonetheless, the widespread availability of free AI tools raises important questions about their impact on learning. Will dependency on AI diminish students' ability to think critically, write persuasively, or master foundational skills like coding and logical reasoning? College remains a critical stage for developing these competencies, foundations that underpin careers in law, finance, education, arts, healthcare, technology and public service. If AI replaces too many opportunities for students to engage deeply with writing, problem-solving, and conceptual understanding, we risk cultivating a generation overly reliant on AI, similar to needing a calculator for basic math. Therefore, AI companies must carefully consider how to deliver tools that truly motivate students to learn and to solve hard problems rather than compromising their curiosity and integrity. Instead of offering free AI functions with minimal guidance, they should collaborate with colleges and even k-12 schools to develop educational programs that foster critical thinking, creativity, and mastery of core skills. The goal should be to empower students to adapt to an AI-driven world, rather than fostering dependence or complacency. Integrating AI into education offers tremendous promise, but it also demands responsible stewardship. Enterprises, educators, and policymakers must collaborate to ensure AI serves as a tool for empowerment and skill-building. Only then can we prepare a future workforce capable of harnessing AI's benefits, while maintaining the essential skills such as lucid writing, logical reasoning, critical thinking and ethical judgment.
Yahoo
34 minutes ago
- Yahoo
OneShield to Launch Industry's First AI Hub to Accelerate Safe and Scalable Insurance Innovation
MARLBOROUGH, Mass., August 07, 2025--(BUSINESS WIRE)--OneShield, a leading provider of core insurance technology solutions for property and casualty insurers and MGAs, today announced the launch of the OneShield AI Hub, the industry's first centralized environment for the secure development, deployment, and governance of artificial intelligence (AI) solutions within the insurance software ecosystem. The AI Hub will serve as a centralized, secure environment where OneShield team members, clients, and partners come to learn, build, and deploy AI solutions tailored to the OneShield ecosystem. At launch, it will provide internal teams with a foundational set of AI agents and tools powered by large language models (LLMs), enabling the safe, secure, and accelerated delivery of high-impact use cases. Doug Moore, Chief Innovation Officer, described the AI Hub as a breakthrough in how AI solutions are being designed with industry-standard interoperability. "What makes the AI Hub special is its intentional design for interoperability and scale," Moore said. "By grounding our use cases in Model Context Protocol (MCP) and Agent-to-Agent (A2A) standards, we're not just automating, we're laying the foundation for a truly intelligent, collaborative ecosystem across carriers, MGAs, and third-party tools." The OneShield AI Hub will house use cases currently in development across the company's core product lines: OneShield Enterprise (OSE) and OneShield Market Solutions (OMS). Liza Petrie, President of OneShield Enterprise (OSE), highlighted the transformational potential of one of the first use cases: "We're leveraging AI to rethink how we configure and deploy products fundamentally. One of our first use cases leverages an AI agent that can parse and structure SERFF filings in minutes. What once took hours of manual effort now takes seconds, and this is just the beginning." Rex Blazevich, President of OneShield Market Solutions (OMS), emphasized how the AI Hub will streamline delivery while amplifying the value of existing work: "AI use cases like automated claims triage and intelligent policy summarization are already underway. What the AI Hub gives us is a shared foundation of tools, security, and governance that accelerates delivery while ensuring quality and compliance." Tony Villa, CEO of OneShield, added, "I am excited to show our customers and partners the future of insurance technology being built by the OneShield team. I look forward to seeing how the AI Hub transforms not only how we build and deliver software but also how we empower insurers to operate faster, smarter, and with greater agility than ever before. This is more than a technology launch; it's the start of a new era of intelligent insurance operations." About OneShield OneShield provides business solutions for P&C insurers and MGAs of all sizes. OneShield's SaaS platforms include enterprise-level policy management, billing, claims, rating, relationship management, product configuration, business intelligence, and smart analytics. Designed specifically for personal, commercial, and specialty insurance, our solutions support over 90 lines of business. OneShield's clients, some of the world's leading insurers, benefit from optimized workflows, pre-built content, seamless upgrades, collaborative implementations, and pricing models designed to lower the total cost of ownership. Our global footprint includes corporate headquarters in Marlborough, MA, with additional offices in India. For more information, visit View source version on Contacts For more information or to schedule a media interview, please contact: Kaitlyn Jakovcic Senior Product Marketing ManagerOneShieldT: 774.348.1000 | E: kjakovcic@
